74. Clinical and Microbiology Outcomes of Bloodstream Infections (BSI) in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HCT) in a Randomized, Double-blind, Placebo-controlled Cohort 2 of a Phase 1b Study of SER-155, an Investigational Live Biotherapeutic

TL;DR

A new oral treatment called SER-155 may reduce bloodstream infections in patients undergoing a type of stem cell transplant.

Contribution

SER-155, a live biotherapeutic, significantly reduced bloodstream infections in a clinical trial for patients undergoing allogeneic hematopoietic stem cell transplants.

Findings

SER-155 was associated with a 10% incidence of BSI compared to 43% in the placebo group.

All BSI occurred before neutrophil recovery and were treated with standard antimicrobial care.

Participants receiving placebo with multidrug-resistant BSI had fatal outcomes.

Abstract

SER-155 is an investigational, oral live biotherapeutic, comprised of 16 bacterial strains, designed to protect GI mucosal barrier integrity and prevent BSI in patients receiving allo-HCT. FDA granted Breakthrough Therapy Designation to SER-155 based on results of a Phase 1b trial in adults undergoing allo-HCT that showed SER-155 was well-tolerated and associated with significantly lower incidence of BSI compared with placebo (10% vs 43%, respectively; Odds Ratio 0.15 [95% CI, 0.01-1.13]; p=0.0423). Concentrations of fecal albumin, a biomarker of impaired GI barrier integrity, were significantly higher (p=0.04; post hoc) pre-HCT in participants with BSI post-HCT, consistent with the GI translocation hypothesis of BSI pathogenesis. Here, we report new post hoc summaries of clinical and microbiology outcomes in participants with BSI.

Adult patients were randomized 1:1 to receive vancomycin/SER-155 or placebo/placebo administered ppre-HCT and post-neutrophil recovery (Figure 1). BSI within HCT Day 0-100 were summarized by treatment arm, causative organism, clinical outcome, antibacterial prophylaxis (AP), and antimicrobial resistance (AMR) test results.

34 participants (SER-155 = 20; placebo = 14) were treated and received allo-HCT. 2 (10%) treated with SER-155 and 6 (43%) treated with placebo had BSI caused by ≥1 bacterial or fungal organism. 2 BSI were polymicrobial. Organisms were consistent with typical BSI pathogens after allo-HCT; no SER-155 species were identified in any BSI. All BSI occurred between HCT Days 4 and 15, before neutrophil recovery. All BSI were treated with antimicrobial agents as per local standard of care. 2 of 6 placebo participants had fatal outcomes (Table 1). All participants with BSI received AP, with all but 1 receiving a fluoroquinolone (FQ). All FQ resistant BSI bacteria were in participants receiving FQ AP. 5 of 6 placebo, but 0 of 2 SER-155, participants had BSI bacteria with multidrug AMR (MDR) (Table 2).

BSI incidence was lower with SER-155 than placebo, and BSI occurred despite AP. BSI bacteria exhibited high prevalence FQ resistance and other AMR, consistent with published reports of BSI bacteria in allo-HCT. Two placebo participants with MDR BSI bacteria had fatal outcomes.

Tessa Andermann, MD, MPH, Seres Therapeutics: Advisor/Consultant

Figures